健康元药业集团 关于使用闲置自有资金投资结构性存款的公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-033 健康元药业集团股份有限公司 关于使用闲置自有资金投资结构性存款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1、投资目的 在不影响公司主营业务的发展的前提下，健康元药业集团股份有限公司（以下简 称：本公司）使用闲置的自有资金投资银行发行的结构性存款，将有利于提高资金的 使用效率，增加投资收益。 2、投资金额 本公司使用闲置自有资金投资银行发行的结构性存款的额度上限为人民币29亿 元（含），在额度内资金可滚动使用，任一时点的交易金额（含前述投资的收益进行 再投资的相关金额）不超过上述投资额度。 重要内容提示： ●投资种类：安全性高、流动性好、风险等级低的银行结构性存款； ●投资金额：公司使用闲置自有资金投资银行发行的结构性存款的额度上限为人 民币29亿元（含），额度内资金可滚动使用，任一时点的交易金额（含前述投资的收 益进行再投资的相关金额）不超过上述投资额度； ●特别风险提示：本次投资结 ...

健康元药业集团 关于召开 2024 年度暨2025年第一季度业绩暨现金分红说明会的公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-037 健康元药业集团股份有限公司关于召开 2024 年度暨 2025 年第一季度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2025 年 05 月 12 日（星期一） 15:00-17:00 ●会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心视频与网络文字互动 ●投资者可于 2025 年 04 月 30 日 （星期三）至 05 月 09 日（星期五）16:00 前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 joincare@joincare.com 进行提问， 公司将在说明会上对投资者普遍关注的问题进行回答。 健康元药业集团股份有限公司（以下简称：本公司）已于 2025 年 4 月 8 日及 2025 年 ...

一、召开会议的基本情况 重要内容提示： ●股东大会召开日期：2025 年 6 月 6 日 ●本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 ●公司拟使用上证所信息网络有限公司（以下简称"上证信息"）提供的股东 大会提醒服务，委托上证信息通过智能短信等形式，根据股权登记日的股东名册主 动提醒股东参会投票，向每一位投资者主动推送股东会参会邀请、议案情况等信息。 健康元药业集团 关于召开 2024 年年度股东大会的通知 证券代码：600380 证券简称：健康元 公告编号：临 2025-036 健康元药业集团股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1、股东大会类型和届次 2024年年度股东大会 2、股东大会召集人：董事会 3、投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方 式 4、现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 6 日 14 点 00 分 召开地点：深圳市南山区高新区北区朗山路 17 号健康元药业 ...

健康元药业集团 2024 年年度股东大会会议资料 健康元药业集团股份有限公司 2024年年度股东大会会议资料 二〇二五年四月 1 / 40 | 2024 | 年年度股东大会会议议程安排 3 | | --- | --- | | 审议《2024 | 年度监事会工作报告》 4 | | 审议《2024 | 年度董事会工作报告》 9 | | 审议《2024 | 年度财务决算报告》 20 | | 审议《2024 | 年度利润分配方案》 26 | | 审议《健康元药业集团股份有限公司 | 2024 年年度报告（全文及摘要）》 27 | | 内部控制审计报告〉的议案》 28 | | | 表的专项审核报告》 29 | | | 审议《关于本公司授信融资及为下属子公司提供融资担保的议案》 30 | | | 审议《关于本公司及控股子公司焦作健康元为金冠电力贷款提供担保的议案》 37 | | | 案》 39 | | | 听取《2024 | 年度独立董事述职报告》 40 | 健康元药业集团 2024 年年度股东大会会议资料 健康元药业集团股份有限公司 2024年年度股东大会会议议程安排 一、现场会议时间：2025年6月6日 14:00 ...

事件： 公司发布2024 年度报告。根据2024 年公司年报，公司实现营业收入156.19 亿元，同比下降6.17%；归 母净利润 13.87 亿元，同比下降 3.90%；扣非归母净利润为 13.19 亿元，同比下降 3.99%；EPS 为0.74 元/股，同比下降2.63%，基本符合预期。 核心要点： 抗感染恢复增长，呼吸业务集采影响显现，保健及 OTC 增长53.91%近几年处方药业务存量核心品种相 继受到集采影响，从影响节奏来看，抗感染集采影响消退，恢复增长，同比增长9.69%。左沙丁胺醇集 采报表影响显现，同时叠加2023 年呼吸疾病高基数因素，导致呼吸业务收入同比下滑36.98%。预计 2025 年集采影响边际逐步减弱。 保健食品及 OTC 板块保持快速增长，受益于品牌数字营销体系建设，板块实现营业收入6.97 亿元，同 比增长53.91%。 原料药及中间体板块整体保持相对稳定，实现营业收入20.25 亿元，同比下降2.63%。其中，7-ACA 价 格呈现稳定增长态势，美罗培南原料药受价格下滑，市场竞争加剧等因素影响，收入有所下滑。 丽珠单抗（持股54.52%）较去年同期减亏 3.18 亿元。丽珠单 ...

本次电话会议仅服务于星叶证券客户会议音频及文字记录的内容版权为星叶证券所有内容必须经星叶证券审核后方可留存未经允许和授权专载转发此次会议内容均属侵权星叶证券将保留追究其法律责任的权利 召开会议所有参会人员不能泄露内幕信息以及未公开重要信息涉及外部嘉宾发言的商业证券不保障其发言内容的准确性与完整性商业证券不承担外部嘉宾发言内容所引起的任何损失及责任不承担因转载转发引起的任何损失及责任市场有风险投资需谨慎提醒投资者 好的各位领导各位投资者上午好那么今天我们非常高兴可以邀请到回家时代的副总兼总理张飞总来给我们分享一下公司2024年的经营情况以及后续的一些展望 那么我们先请张培总来分析一下整个年报的一些重点和亮点的一些变化那么以及后续的一些规划那么后续呢我们可以再进入到问答环节有请张培总 好的各位上午好那么公司之后年报大家其实已经看到就是我们整个二四年的一个整个经营业绩呢是较二三年是有所下降的那么收入端可能下降的幅度稍微较小一点但是从利润端来看的话呢其实我们整个受大的这个环境的影响还是比较大所以我们这块利润端呢相较二三年同期下降的幅度也比较大 自2014年我们还是整体在年初制定的整个精英计划的这个基础上 整个还是按照 ...

Core Viewpoint - The company Health元 (600380.SH) continues to face operational pressure due to a complex external environment, with both revenue and net profit declining for the second consecutive year in 2024 [1][6]. Financial Performance - In 2024, Health元 reported revenue of 15.619 billion and a net profit attributable to shareholders of 1.387 billion, representing a year-on-year decline of 6.17% and 3.90% respectively [4][6]. - The company has experienced a rare occurrence of consecutive declines in revenue and net profit, with the last similar instance occurring in 2023 [6][7]. - Quarterly revenue for 2024 showed a consistent decline across all four quarters, with figures of 4.340 billion, 3.895 billion, 3.664 billion, and 3.721 billion, reflecting year-on-year decreases of 4.81%, 6.39%, 6.80%, and 6.87% respectively [7][8]. Research and Development - Despite increasing focus on innovative drug development, Health元's R&D investment has been decreasing, with 2024 R&D spending at 1.532 billion, down 318 million from 2021 [2][11]. - The proportion of R&D investment relative to revenue has also declined, from 11.63% in 2021 to 9.81% in 2024 [11]. - The company has reduced its R&D personnel by 70 in 2024, with the total number of R&D staff at 1,670, accounting for 11.63% of total employees [10][11]. Dividend Policy - Health元's dividend distribution remains low, with a proposed cash dividend of 366 million for 2024, resulting in a dividend payout ratio of 26.39% [2][12]. - The company has maintained a dividend payout ratio below 30% for five consecutive years [3][13]. Cost Management - Health元 has managed to reduce sales and management expenses, totaling a decrease of 755.6 million in 2024 compared to 2023 [8][9]. - Despite the reduction in expenses, the company's net profit continued to decline, indicating challenges in reversing the downward trend in operational performance [9]. Cash Position - As of the end of 2024, Health元 reported cash and cash equivalents of 14.852 billion, with interest-bearing liabilities of 5.276 billion, indicating a strong liquidity position [15].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][6][16] Core Views - The company achieved a revenue of 15.619 billion yuan in 2024, a year-on-year decrease of 6.17%, with a net profit attributable to shareholders of 1.387 billion yuan, down 3.90% year-on-year [6] - The gross margin for 2024 was 62.69%, an increase of 0.53 percentage points, while the net margin was 19.10%, up 1.97 percentage points [6] - The company is in a product transition phase, with sales of Tobramycin and Shuleide gradually improving, and new drugs like TG-1000 expected to contribute to revenue growth [6][8] Financial Summary - In Q4 2024, the company reported a revenue of 3.721 billion yuan, a decrease of 6.87% year-on-year but an increase of 1.54% quarter-on-quarter [6] - The projected net profits for 2025, 2026, and 2027 are 1.463 billion yuan, 1.568 billion yuan, and 1.715 billion yuan respectively, with corresponding EPS of 0.80 yuan, 0.86 yuan, and 0.94 yuan [6][10] - The current price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are projected to be 13.3, 12.4, and 11.3 respectively [6][10] Business Performance - The company’s revenue from hormone products was 2.812 billion yuan, up 1.64% year-on-year, while respiratory system products saw a significant decline of 36.98% to 1.097 billion yuan [7] - The health food segment experienced substantial growth, with revenue increasing by 92.32% to 377 million yuan, and biological products revenue surged by 102.42% to 171 million yuan [7] - The company is focusing on a comprehensive matrix for respiratory diseases, with several innovative drugs making significant progress in clinical trials [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][6][16] Core Views - The company achieved a revenue of 15.619 billion yuan in 2024, a year-on-year decrease of 6.17%, with a net profit attributable to shareholders of 1.387 billion yuan, down 3.90% year-on-year [6] - The gross margin for 2024 was 62.69%, an increase of 0.53 percentage points, while the net margin was 19.10%, up 1.97 percentage points [6] - The company is in a product transition phase, with the sales of Tobramycin and Shulide gradually improving, and new drugs like TG-1000 expected to contribute to revenue growth [6][8] Financial Summary - In 2024, the company reported a quarterly revenue of 3.721 billion yuan in Q4, a decrease of 6.87% year-on-year but an increase of 1.54% quarter-on-quarter [6] - The projected net profits for 2025, 2026, and 2027 are 1.463 billion yuan, 1.568 billion yuan, and 1.715 billion yuan respectively, with corresponding EPS of 0.80 yuan, 0.86 yuan, and 0.94 yuan [6][10] - The current price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are 13.3, 12.4, and 11.3 respectively [6][10] Business Performance - The company’s revenue from hormone products was 2.812 billion yuan in 2024, up 1.64% year-on-year, while respiratory system products saw a significant decline of 36.98% to 1.097 billion yuan [7] - The health food segment experienced substantial growth, with revenue increasing by 92.32% to 377 million yuan, and biological products revenue surged by 102.42% to 171 million yuan [7] - The company is focusing on a comprehensive matrix for respiratory diseases, with several innovative drugs making significant progress in clinical trials [8]

Core Viewpoint - The article discusses the performance and transformation of the company, Health元, from a generic drug manufacturer to an innovative pharmaceutical enterprise, highlighting its financial results and strategic advancements in the respiratory drug market [2][3][10]. Financial Performance - As of April 7, 2024, Health元 reported a total revenue of 156.19 billion yuan and a net profit of 13.87 billion yuan for the fiscal year [2][4]. - The company has shown consistent growth, with total revenue exceeding 1,127.88 billion yuan and net profit surpassing 105.07 billion yuan from 2017 to 2024 [5][6]. - The revenue and net profit figures for the years 2017 to 2024 are as follows: - 2017: Revenue 107.79 billion yuan, Net Profit 21.33 billion yuan - 2018: Revenue 112 billion yuan, Net Profit 6.99 billion yuan - 2019: Revenue 119.8 billion yuan, Net Profit 8.94 billion yuan - 2020: Revenue 135.2 billion yuan, Net Profit 11.2 billion yuan - 2021: Revenue 159 billion yuan, Net Profit 13.28 billion yuan - 2022: Revenue 171.4 billion yuan, Net Profit 15.03 billion yuan - 2023: Revenue 166.5 billion yuan, Net Profit 14.43 billion yuan - 2024: Revenue 156.19 billion yuan, Net Profit 13.87 billion yuan [5][6]. Innovation and R&D - Health元 has transitioned to focus on innovative drugs, achieving significant breakthroughs in respiratory, analgesic, digestive, and psychiatric treatment areas [2][3]. - The company has developed 10 products in the respiratory field, with its first product,舒坦琳, achieving a 22-fold increase in sales over four years, establishing a leading position in the domestic respiratory market [2][3]. - Health元 has maintained a commitment to R&D, investing approximately 10% of its profits annually, with a total R&D expenditure of 15.32 billion yuan in 2024 [8][9]. Cash Flow and Shareholder Returns - The company has a strong cash flow, essential for sustaining operations in the high-investment pharmaceutical industry, and has maintained a stable cash flow while investing in R&D [6][7]. - Health元 has distributed a total of 39.79 billion yuan in dividends over 21 occasions since its listing in 2001, with a payout ratio of 89.37% [7][8]. - The company has executed share buybacks totaling nearly 40 billion yuan, enhancing shareholder value through share reduction and increased earnings per share [8][9].